Glucosamine Conjugated Gadolinium (Iii) Oxide Nanoparticles As a Novel Targeted Contrast Agent for Cancer Diagnosis in Mri

Glucosamine Conjugated Gadolinium (Iii) Oxide Nanoparticles As a Novel Targeted Contrast Agent for Cancer Diagnosis in Mri Publisher

Mortezazadeh T^{1, 2} ; Gholibegloo E³ ; Riyahi AN¹ ; Haghgoo S⁴ ; Musa AE¹ ; Khoobi M³

Show Affiliations

1. Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, Iran
2. Department of Medical Physics, School of Medicine, Tabriz University of Medical Science, Tabriz, Iran
3. Department of Pharmaceutical Biomaterials and Medical Biomaterials Research Center (MBRC), Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
4. Pharmaceutical Department, Food and Drug Laboratory Research Center, Food and Drug Organization (FDO), Ministry of Health, Tehran, Iran

Source: Journal of Biomedical Physics and Engineering Published:2020

Abstract

Background: Glucose transporter (Glut), a cellular transmembrane receptor, has a key role in the metabolism of cell glucose and is also associated with various human carcinomas. Objective: In this study, we evaluated a magnetic resonance (MR) imaging contrast agent for tumor detection based on paramagnetic gadolinium oxide (Gd2 O3) coated polycyclodextrin (PCD) and modified with glucose (Gd2 O3 @PCD-Glu) for the targeting of overexpressed glucose receptors. Material and Methods: In this experimental study, 3T magnetic resonance imaging (MRI) scanner was used to assess the specific interactions between Glut1-overexpressing tumor cells (MDA-MB-231) and Gd2 O3 @PCD-Glu NPs. Furthermore, the capacity of transporting Gd2 O3 @PCD-Glu NPs to tumor cells was evaluated. Results: It was found that the acquired MRI T1 signal intensity of MDA-MB-231 cells that were treated with the Gd2 O3 @PCD-Glu NPs increased significantly. Based on the results obtained, Gd2 O3 @PCD-Glu NPs can be applied in targeting Glut1-overexpressing tumor cells in vivo, as well as an MRI-targeted tumor agent to enhance tumor diagnosis. Conclusion: Results have shown that glucose-shell of magnetic nanoparticles has a key role in diagnosing cancer cells of high metabolic activity. © 2020, Shiraz University of Medical Sciences. All rights reserved.

Related Docs

View other Related Docs

1. In Vitro and In Vivo Characteristics of Doxorubicin-Loaded Cyclodextrine-Based Polyester Modified Gadolinium Oxide Nanoparticles: A Versatile Targeted Theranostic System for Tumour Chemotherapy and Molecular Resonance Imaging, Journal of Drug Targeting (2020)

2. Gadolinium (Iii) Oxide Nanoparticles Coated With Folic Acid-Functionalized Poly(Β-Cyclodextrin-Co-Pentetic Acid) As a Biocompatible Targeted Nano-Contrast Agent for Cancer Diagnostic: In Vitro and in Vivo Studies, Magnetic Resonance Materials in Physics# Biology and Medicine (2019)

3. A Biocompatible Theranostic Nanoplatform Based on Magnetic Gadolinium-Chelated Polycyclodextrin: In Vitro and in Vivo Studies, Carbohydrate Polymers (2021)

4. Lymph Node Metastases Detection Using Gd2o3@Pcd As Novel Multifunctional Contrast Imaging Agent in Metabolic Magnetic Resonance Molecular Imaging, Contrast Media and Molecular Imaging (2022)

5. Folic Acid Decorated Magnetic Nanosponge: An Efficient Nanosystem for Targeted Curcumin Delivery and Magnetic Resonance Imaging, Journal of Colloid and Interface Science (2019)

6. Nsf Evaluation of Gadolinium Biodistribution in Renally Impaired Rats: Using Novel Metabolic Gd2o3 Nanoparticles Coated With Β-Cyclodextrin (Gd2o3@Pcd) in Mr Molecular Imaging, Magnetic Resonance Imaging (2024)

7. Curcumin-Lipoic Acid Conjugate As a Promising Anticancer Agent on the Surface of Gold‑Iron Oxide Nanocomposites: A Ph-Sensitive Targeted Drug Delivery System for Brain Cancer Theranostics, European Journal of Pharmaceutical Sciences (2018)

8. Degradation of Tetracycline Using a Magnetic Gadolinium-Decorated Nanoplatform: A Peroxidase Biomimetic System With Fenton-Like Catalysis, Water (Switzerland) (2023)

Experts (# of related papers)

View all Related Experts

Mehdi Khoobi (16)

Sadegh Dehghani (5)

Style	Citing Format
MLA	Mortezazadeh T, et al.. "Glucosamine Conjugated Gadolinium (Iii) Oxide Nanoparticles As a Novel Targeted Contrast Agent for Cancer Diagnosis in Mri." Journal of Biomedical Physics and Engineering, vol. 10, no. 1, 2020, pp. 25-38.
APA	Mortezazadeh T, Gholibegloo E, Riyahi AN, Haghgoo S, Musa AE, Khoobi M (2020). Glucosamine Conjugated Gadolinium (Iii) Oxide Nanoparticles As a Novel Targeted Contrast Agent for Cancer Diagnosis in Mri. Journal of Biomedical Physics and Engineering, 10(1), 25-38.
Chicago	Mortezazadeh T, Gholibegloo E, Riyahi AN, Haghgoo S, Musa AE, Khoobi M. "Glucosamine Conjugated Gadolinium (Iii) Oxide Nanoparticles As a Novel Targeted Contrast Agent for Cancer Diagnosis in Mri." Journal of Biomedical Physics and Engineering 10, no. 1 (2020): 25-38.
Harvard	Mortezazadeh T et al. (2020) 'Glucosamine Conjugated Gadolinium (Iii) Oxide Nanoparticles As a Novel Targeted Contrast Agent for Cancer Diagnosis in Mri', Journal of Biomedical Physics and Engineering, 10(1), pp. 25-38.
Vancouver	Mortezazadeh T, Gholibegloo E, Riyahi AN, Haghgoo S, Musa AE, Khoobi M. Glucosamine Conjugated Gadolinium (Iii) Oxide Nanoparticles As a Novel Targeted Contrast Agent for Cancer Diagnosis in Mri. Journal of Biomedical Physics and Engineering. 2020;10(1):25-38.
BibTex	@article{ author = {Mortezazadeh T and Gholibegloo E and Riyahi AN and Haghgoo S and Musa AE and Khoobi M}, title = {Glucosamine Conjugated Gadolinium (Iii) Oxide Nanoparticles As a Novel Targeted Contrast Agent for Cancer Diagnosis in Mri}, journal = {Journal of Biomedical Physics and Engineering}, volume = {10}, number = {1}, pages = {25-38}, year = {2020} }
RIS	TY - JOUR AU - Mortezazadeh T AU - Gholibegloo E AU - Riyahi AN AU - Haghgoo S AU - Musa AE AU - Khoobi M TI - Glucosamine Conjugated Gadolinium (Iii) Oxide Nanoparticles As a Novel Targeted Contrast Agent for Cancer Diagnosis in Mri JO - Journal of Biomedical Physics and Engineering VL - 10 IS - 1 SP - 25 EP - 38 PY - 2020 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract